On the HCPLive Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.
April 30th 2024
USPSTF now advises biennial breast cancer screening from age 40 to 74 years based on an evolving evidence base.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
May 21, 2024
Register Now!
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Multiple Myeloma from the Summer Meetings
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Oncology Briefings™: Updates in the Care of Patients with ITP – Evaluating the Role of the Nurse
View More
Oncology Briefings: How Do We Integrate New Data and Treatment Options to Optimize Outcomes for Patients with Hemolytic Anemias?
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Clinical ShowCase™: Taking Control of Paroxysmal Nocturnal Hemoglobinuria
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Stem Cell Transplantation May Hold Promise for HIV Infection Eradication
Two male patients with prolonged HIV infection who received hematopoietic stem cell transplants still remain virus-free several consecutive weeks after their antiretroviral treatments were discontinued this spring.
FDA Expands Exelon Patch Approval to Treat Severe Alzheimer's Disease
The US Food and Drug Administration (FDA) has expanded the indications of Novartis Pharmaceuticals Corp.'s transdermal therapy for Alzheimer's disease to include the treatment of patients with severe stages of the neurological disorder.
As pre-exposure prophylaxis (PrEP) remains at the forefront of HIV prevention research, clinical trial investigators provided an update on recent oral and topical PrEP efficacy studies at the second plenary session of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), held June 30 to July 3 in Kuala Lumpur, Malaysia.
FDA Approves First Non-Hormonal Treatment for Menopausal Hot Flashes
The US Food and Drug Administration (FDA) has approved Noven Pharmaceuticals Inc.'s once-daily Brisdelle (paroxetine) capsules to reduce moderate to severe hot flashes and night sweats that can last up to five years in menopausal women.
Postmenopausal Women with IBS-C Benefit from Melatonin More than IBS-D Counterparts
Recognizing that melatonin secretion from the gastrointestinal (GI) tract improves abdominal pain in irritable bowel syndrome (IBS) but decreases with age, Polish researchers from the Medical University of Lodz aimed to define the effect of administering melatonin in postmenopausal women with different predominating IBS symptoms.
Long-Term Raltegravir Effective in HIV Patients with Drug Resistance, Past Virological Failure
Results of a pair of phase 3 placebo-controlled clinical studies conducted by a worldwide team of researchers have deemed Merck's Isentress (raltegravir) antiretroviral treatment safe, tolerable, and effective in multidrug-resistant HIV patients who are naïve to integrase inhibitors.
Promising Heart Failure Drug Receives ‘Breakthrough' FDA Designation
The US Food and Drug Administration has awarded "breakthrough therapy" status to a synthetic copy of a naturally occurring human hormone for the treatment of acute heart failure (AHF), drug developer Novartis announced today.
Liver Abnormalities Lead Lilly to Halt Alzheimer's Drug Development
Nearly two years after Eli Lilly and Co. halted a pair of clinical trials on its gamma-secretase inhibitor for Alzheimer's disease following the candidate's failure to demonstrate results superior to placebo, the drug maker has terminated a phase 2 study of its investigational beta-secretase (BACE) inhibitor for the same neurological condition - this time citing liver abnormalities.
Study Supports Injected Methylcobalamin for Subacute Herpetic Neuralgia Treatment
Results of a recent clinical trial by researchers at the Department of Rehabilitation Medicine in the Affiliated Tenth People's Hospital of Tongji University, in Shanghai, China, have deemed locally injected methylcobalamin more effective than its orally administered counterpart as a treatment for subacute herpetic neuralgia.
Researcher Sorts Through Sea of IBS Remedies
May 22nd 2013As irritable bowel syndrome (IBS) remains a complicated condition to treat with an etiology that's still unknown, it's difficult for physicians to find the best proven therapies among new remedies and the variety of pharmacological and nondrug options they have been trying for years.
Colonoscopy Prevents Crohn's Disease Post-Operative Endoscopic Recurrence
May 22nd 2013While it's already clinically understood that most patients with Crohn's disease suffer a recurrence following an intestinal resection, researchers have not evaluated the best strategy to prevent the disease from recurring.
Abdominal, Bowel Symptom Improvement From Linaclotide Meets FDA Standards for IBS-C
May 21st 2013Patients taking linaclotide experience clinically meaningful improvement in abdominal and bowel symptoms, which closely correlate with the US Food and Drug Administration's new criteria for irritable bowel syndrome with constipation (IBS-C).
Cost-Effective pH Testing Can Rule Out GERD
May 20th 2013Esophageal pH monitoring is more cost effective than the long-term use of proton-pump inhibitors (PPIs), since it can help rule out gastroesophageal reflux diseases (GERD) and avoid the unneeded costs associated with prolonged medication therapy.